Wealthfront Advisers LLC Decreases Position in Zoetis Inc. $ZTS

Key Points

• Wealthfront Advisers LLC cut its stake in Zoetis by 59.2% in Q4, selling 22,026 shares and leaving 15,194 shares valued at $1.912 million per its latest 13F filing.
• Zoetis beat quarterly expectations with $1.48 EPS (vs. $1.40 est.) and $2.39 billion in revenue, and set FY2026 guidance of $7.00–$7.10 EPS (sell-side average ~7.01).
• Vanguard raised its holding by 12.9% to about 47.78 million shares (~$6.01 billion), and institutional investors collectively own roughly 92.8% of Zoetis stock.

Wealthfront Advisers LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 59.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,194 shares of the company's stock after selling 22,026 shares during the period. Wealthfront Advisers LLC's holdings in Zoetis were worth $1,912,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock valued at $6,011,802,000 after buying an additional 5,474,210 shares during the period. Nordea Investment Management AB boosted its position in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after buying an additional 2,179,578 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company's stock valued at $631,046,000 after buying an additional 550,859 shares during the period. Alliancebernstein L.P. boosted its position in Zoetis by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company's stock valued at $620,595,000 after buying an additional 496,320 shares during the period. Finally, Fundsmith LLP boosted its position in Zoetis by 25.3% in the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company's stock valued at $528,966,000 after buying an additional 730,300 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

Shares of ZTS opened at $114.22 on Friday. Zoetis Inc. has a 1-year low of $112.97 and a 1-year high of $172.23. The stock has a market cap of $48.05 billion, a PE ratio of 18.97, a price-to-earnings-growth ratio of 1.76 and a beta of 0.87. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a fifty day moving average price of $119.93 and a 200 day moving average price of $124.67.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion during the quarter, compared to analysts' expectations of $2.36 billion. During the same period in the previous year, the company earned $1.40 earnings per share. Zoetis's quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 7.01 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis's dividend payout ratio is presently 35.22%.

Analyst Ratings Changes

Several research firms have recently issued reports on ZTS. Piper Sandler reaffirmed a "neutral" rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Weiss Ratings cut shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, March 27th. BTIG Research reaffirmed a "buy" rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. William Blair reaffirmed an "outperform" rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, UBS Group decreased their price objective on shares of Zoetis from $136.00 to $130.00 and set a "neutral" rating for the company in a research report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $151.75.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.